| HDCV | Human Diploid Cell Vaccine; 인간 이배체 세포 백신 |
|---|---|
| NTV | Nervous Tissue Vaccine; 신경 조직 백신 |
| OPV | Oral Polio-Vaccine; 경구용 소아마비 백신 |
| TOPV | Trivalent Oral Polio(myelitis) Vaccine; 경구용 소아마비 혼합백신 |
| BCG | bacille Calmette-Guerin [vaccine]; ballistocardiography, ballistocardiogram; bicolor guaiac test; br... |
| inactivated polio vaccine | <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years. (27 Sep 1997) |
|---|---|
| inactivated poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| influenza vaccine | A special vaccine which provides immunity to infection by a variety of Influenza viruses. The vaccine is updated annually due to the constant introduction of new viral strains. Flu vaccination programs are common in the elderly population and any other groups who are at increased risk of viral infection. (27 Sep 1997) |
| oil vaccine | A vaccine that contains an adjuvant; most often the antigen (immunogen) is included in a water-in-oil emulsion (Freund incomplete type adjuvant), or is adsorbed onto an inorganic gel (alum, aluminum hydroxide or phosphate). (05 Mar 2000) |
| oral polio vaccine | <drug> A live vaccination, administered orally to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final oral vaccine is recommended at 4-6 years. (27 Sep 1997) |
| oral poliovirus vaccine | An aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis. See: Sabin vaccine. Synonym: poliomyelitis vaccines. (05 Mar 2000) |
| TAB vaccine | A suspension of killed typhoid and paratyphoid A and B bacilli. See: typhoid vaccine. Synonym: TAB vaccine. (05 Mar 2000) |
| tetanus vaccine | See: diphtheria toxoid, tetanus toxoid, and pertussis vaccine. (05 Mar 2000) |
| therapeutic vaccine | An injected therapy consisting of synthetic HIV antigen (for example, gp160) that is administered to people who already have HIV It is supposed to heighten and broaden the immune response to HIV, helping to halt disease progression. (09 Oct 1997) |
| tuberculosis vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| typhoid-paratyphoid A and B vaccine | A suspension of killed typhoid and paratyphoid A and B bacilli. See: typhoid vaccine. Synonym: TAB vaccine. (05 Mar 2000) |
| typhoid vaccine | A suspension of Salmonella typhi inactivated either by heat or by chemical (acetone) with an added preservative; in the U.S., the combined typhoid and paratyphoid A and B vaccine's have been largely replaced by the monovalent typhoid vaccine because of the lack of evidence of effectiveness of paratyphoid A and paratyphoid B ingredients. (05 Mar 2000) |
| typhus vaccine | A formaldehyde-inactivated suspension of Rickettsia prowazekii grown in embryonated eggs; effective against louse-borne (epidemic) typhus; primary immunization consists of two subcutaneous injections 4 or more weeks apart; booster doses are required every 6 to 12 months, as long as the possibility of exposure exists. A vaccine containing living rickettsiae of an attenuated strain of R. Prowazekii has also been used. (05 Mar 2000) |
| yellow fever vaccine | A living, attenuated strain (17D) of yellow fever virus propagated in embryonated fowl eggs. A suspension of dried mouse brain infected with French neurotropic (Dakar) strain of yellow fever virus, administered topically by the scratch method; not officially recommended in the United States because of meningoencephalitic reactions. (05 Mar 2000) |
| Flury strain vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |